Growth Regulated Oncogene-α Upregulates TNF-α and COX-2 and Activates NOD1/RIPK2 mediated-MAPK Pathway in Head and Neck Squamous Cell Carcinoma

Leong-Perng Chan1,2,*, Ya-Ping Tseng3, Hui-Ching Wang4, Chen-Yu Chien1,5, Che-Wei Wu1, Ling-Feng Wang1 and Chia-Hua Liang6,***

1. Department of Otorhinolaryngology-Head and Neck Surgery, Kaohsiung Medical University Hospital, Faculty of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan
2. Department of Otorhinolaryngology-Head and Neck Surgery, Kaohsiung Municipal Ta-Tung Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
3. Institute of Basic Medical Sciences, National Cheng Kung University, Tainan, Taiwan
4. Department of Internal Medicine, Division of Hematology and Oncology, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
5. Department of Otolaryngology-Head and Neck Surgery, Kaohsiung Municipal Siaogang Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan
6. Department of Cosmetic Science and Institute of Cosmetic Science, Chia Nan University of Pharmacy and Science, Tainan, Taiwan

*Corresponding authors: LPChan.ent@gmail.com (L.-P. C.); tinna_ling@mail.cnu.edu.tw (C.-H. L.); Tel.: +886-6-2664911 (ext. 2441)

© The author(s). This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/).
See http://ivyspring.com/terms for full terms and conditions.

Received: 2023.01.01; Accepted: 2023.03.25; Published: 2023.04.09

Abstract

**Purpose:** The long-term prognosis and survival rate of patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) are poor, although the identification of specific biomarkers that reveal its nature and aggressiveness has improved it. Growth-related oncogene alpha (Groα) and NOD1 (nucleotide-binding oligomerization domain 1) can be used as prognosis markers to identify subgroups of HNSCC patients with low survival rates and as potential therapeutic targets for HNSCC patients. However, the mechanism associated with the Groα-mediated NOD pathway in HNSCC progression remains unclear.

**Method:** Overall survival analysis and multiple-gene comparison were analyzed using Gene Expression Profiling Interactive Analysis (GEPIA). qRT-PCR and RT-PCR were used to analyze mRNA expression. Microarray, immunofluorescence staining or western blot analyses were carried out to detect protein expression.

**Results:** Groα was significantly higher in the grade 4 HNSCC tumor tissues compared with that in grade 1-3 and healthy subjects. High expression of Groα, NOD1 and RIPK2 (receptor-interacting serine-threonine kinase 2) is correlated with survival rate in HNSCC patients. Treatment of SCC25 and OECM-1 cells with Groα increased the expression of NOD1 and RIPK2 in a concentration-dependent manner. The findings herein reveal the association of Groα, NOD1 and RIPK2 biomarkers with HNSCC carcinogenesis. Moreover, Groα is the major stimulus of inflammatory mediation and promotes TNF-α (tumor necrosis factor-α) and COX-2 (cyclooxygenase-2) expression in HNSCC. Groα induces TNF-α and COX-2 expression through regulation involving ERK (extracellular signal-regulated kinase)-, JNK (C-Jun N-terminal kinase)-, and p38 MAPK (mitogen-activated protein kinase)-dependent signaling pathways.

**Conclusions:** Our findings herein constitute the first evidence that Groα is important in HNSCC progression and metastasis via the NOD1-mediated MAPK pathway, suggesting a role for Groα and NOD1 in mediating metastasis and its potential as a therapeutic target.

Keywords: HNSCC, Groα, NOD1, MAPK, Metastasis

Introduction

Squamous cell carcinoma (SCC) is the most common malignant tumor of the head and neck (HN) and generally detected in the late stages when the cancer has advanced. HNSCC occurs in various locations, including the inner lip, oral cavity, floor of the mouth, larynx, and pharynx. Antibody drugs for
treatment of HNSCC, such as nivolumab, cetuximab, and pembrolizumab, have been developed. However, the five-year survival rate of patients with HNSCC has remained at ~50% for the past 30 years, despite therapeutic advances [1]. Therefore, the identification of more accurate prognosis biomarkers and suitable therapy targets remains the primary focus of HNSCC research.

Chemokines are small molecules that are secreted by cells that have an essential role in chemotaxis and angiogenesis and are moderators of tumor initiation and metastasis [2]. Growth-related oncogene alpha (Groα), also known as CXCL1 (C-X-C motif chemokine ligand 1), is a member of the chemokine (chemotactic cytokines) family and is significantly up-regulated in various inflammatory diseases. It also has a critical role in the setting the tumor microenvironment, tumor progression, metastasis and angiogenesis [3]. A previous report implied that Groα can be used as a prognosis marker to identify subgroups of HNSCC patients with low survival rates and it may be a suitable therapeutic target for such patients [4].

Toll-like receptors (TLRs) and Nod-like receptors (NLRs) are two major classes of innate immune sensor, which provide immediate responses against pathogenic invasion or tissue injury [5]. As a fundamental member of NLR, the NOD1 (nucleotide-binding oligomerization domain 1) has an important role in the induction of innate immune and inflammatory responses. NOD1 has an important role not only in defending hosts against pathogens but also in maintaining tissue homeostasis by regulating cell apoptosis, and the inflammatory and tissue repair responses to injury. Recent studies have shown that NOD1 has an important role in controlling tumorigenesis [6,7]. Several crucial proteins, NOD1, RIPK2 (receptor-interacting serine-threonine kinase 2), caspase-12 and human β Defensin 1, 2, 3 (hBD1, 2, 3) participate in or regulate the NOD1 signaling pathway [8]. Our earlier study demonstrated that higher NOD1 and RIPK2 expressions were detected in the tissues of HNSCC patients than in NCMT (non-cancerous matched tissue), and identified a significant relationship between the increasing NOD1/2 expression and HNSCC progression [9]. NOD1/caspase activation recruitment domain 4 (CARD4) and NOD2/CARD15 gene polymorphisms may be associated with an altered risk of developing various tumors [10]. NOD1/2 interacts with the CARD-containing RIPK2, activating the nuclear factor kappa B (NF-κB) pathway and MAPK (mitogen-activated protein kinase) pathways [11]. At least three MAPK families have been characterized; they are C-Jun N-terminal kinase/stress-activated protein kinase (JNK/SAPK), extracellular signal-regulated kinase (ERK), and p38 kinase [12]. p38 MAPK and NF-κB regulate COX-2 (cyclooxygenase-2) expression in response to TNF-α (tumor necrosis factor-α), interleukin (IL)-1β, and interferon (IFN)-γ, which is composed of complex inflammatory stimuli [13]. A recent study has demonstrated that Groα that is released by spinal astrocytes following inflammation acts on CXCR2 (CXC receptor 2)-expressing spinal neurons to increase ERK activation, synaptic transmission and COX-2 expression in dorsal horn neurons and contributes to the pathogenesis of inflammatory pain [14]. Inhibition of the MAPK signaling cascade pathway resulted in a statistically significant reduction of Groα protein secretion [15]. However, the relationships between 1) the NOD pathway and 2) the MAPK signaling pathway and the expression of Groα from HNSCC progression are poorly understood. This study establishes that Groα affects inflammatory mediators, regulates the NOD and MAPK pathways and is related to HNSCC progression.

Materials and Methods

Patient selection and specimens

Gene Expression Profiling Interactive Analysis (GEPIA) (http://gepia.cancer-pku.cn/) is a website that uses standard processing methods to analyze the mRNA expression data of tumor and normal samples from the Cancer Genome Atlas (TCGA) projects. The expression level, survival rate, and multiple gene comparison were conducted using GEPIA. We also used UALCAN (http://ualcan.path.uab.edu/), which is a website resource for analyzing cancer OMICS data.

This clinical research was approved by the ethics committee of the Kaohsiung Medical University Hospital (KMUHIRB-G(II)-20180051). Sixty-two adult patients were recruited for the trial between Feb. 2019 and Sep. 2021 from the Department of Otolaryngology-Head and Neck Surgery, Kaohsiung Medical University Hospital, Kaohsiung Medical University, Kaohsiung, Taiwan.

Table 1 summarizes the clinical characteristics of the patients and 90% for all HNSCC patients are squamous cell carcinoma. Patients with documented HNSCC of the oral cavity, oropharynx, larynx and hypopharynx were recruited. The ages of the patients ranged from 34 to 78 years (mean, 57.3 years). In total, 62 patients with HNSCC, including 58 males (93.5%) and 4 females (6.5%). The tumor locations were 55 in the oral cavity (88.7%), 1 in the oropharynx (16.1%), and 6 in the hypopharynx (4.8%). 9 patients presented with well differentiation (14.5%), 47 patients with
moderate (75.8%) and 6 patients with poor (9.7%). Half of the patients had late-stage (74.2%) and the others had early-stage (25.8%). Lymph node metastasis occurred in 32 patients (51.6%) and the remaining had 30 patients not lymph node metastasis (48.4%), were analyzed in this retrospective study. All patients had recently been diagnosed with a primary disease, and had not received any treatment in the form of chemotherapy, radiotherapy or alternative remedies.

<table>
<thead>
<tr>
<th>Characteristics</th>
<th>Frequency</th>
<th>%</th>
</tr>
</thead>
<tbody>
<tr>
<td>Numbers (n)</td>
<td>62</td>
<td></td>
</tr>
<tr>
<td>Age (year)</td>
<td>56.5</td>
<td></td>
</tr>
<tr>
<td>Range</td>
<td>34-81</td>
<td></td>
</tr>
<tr>
<td>Gender</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Male</td>
<td>58</td>
<td>93.5</td>
</tr>
<tr>
<td>Female</td>
<td>4</td>
<td>6.5</td>
</tr>
<tr>
<td>Location</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral cavity</td>
<td>55</td>
<td>88.7</td>
</tr>
<tr>
<td>Oropharynx</td>
<td>1</td>
<td>16.1</td>
</tr>
<tr>
<td>Hypopharynx</td>
<td>6</td>
<td>4.8</td>
</tr>
<tr>
<td>Differentiation grade</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Well</td>
<td>9</td>
<td>14.5</td>
</tr>
<tr>
<td>Moderate</td>
<td>47</td>
<td>75.8</td>
</tr>
<tr>
<td>Poor</td>
<td>6</td>
<td>9.7</td>
</tr>
<tr>
<td>Stage</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Early-stages (cT1-2N0M0)</td>
<td>16</td>
<td>25.8</td>
</tr>
<tr>
<td>Late-stages (cT4N0-3M0)</td>
<td>46</td>
<td>74.2</td>
</tr>
<tr>
<td>Lymph node metastasis</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N0</td>
<td>30</td>
<td>48.4</td>
</tr>
<tr>
<td>N1</td>
<td>13</td>
<td>21.0</td>
</tr>
<tr>
<td>N2</td>
<td>8</td>
<td>12.9</td>
</tr>
<tr>
<td>N3</td>
<td>11</td>
<td>17.7</td>
</tr>
</tbody>
</table>

To isolate RNA and protein, tissues, is from biopsies, were placed in fresh-frozen liquid nitrogen and underwent purification for further use in microarray, qRT-PCR, RT-PCR and western blot analyses. For immunofluorescence analysis, HNSCC tissues were fixed in buffered formalin and embedded in paraffin, sliced into 3 μm-thick sections, and mounted on glass slides. Table 2 summarizes relevant information concerning the HNSCC patients.

### Microarray analyses

NCMT (NCMT was sampled 5 cm away from the resection margin) and HNSCC tissue RNA were extracted using Trizol reagent (Invitrogen, Carlsbad, CA, USA), and then the RNeasy Mini Kit (Qiagen, Hilden, Germany) was used to quantify the isolated RNA isolated at OD 260 nm and qualitatively analyzed using a bioanalyzer (Agilent Technology, USA). A 0.2 μg mass of total RNA was amplified using a Low-Input Quick-Amp Labeling Kit (Agilent Technologies, USA) and labeled with Cy3 (CyDye, Agilent Technologies, USA) during an in vitro transcription process. A 0.6 μg mass of Cy3-labeled cRNA was fragmented to a mean size of approximately 50-100 nucleotides by incubation with a fragmentation buffer at 60°C for 30 minutes. Correspondingly fragmented labeled cRNA was then pooled and hybridized using an Agilent Sure Print G3 Human V2 GE 6 × 60 K Microarray (Agilent Technologies, USA) at 65°C for 17 h. After the microarrays were washed and dried by blowing with a nitrogen gun, the microarrays were scanned using an Agilent microarray scanner (Agilent Technologies, USA) at 535 nm for Cy3. Scanned images are analyzed using Feature Extraction 10.5.1.1 software (Agilent Technologies, USA) for image analysis and normalization to quantify the signal and background intensity for each feature (Welige Biotech. Co., Taipei, Taiwan). Raw signal data was normalized by quantile normalization for differential expressed genes discovering.

### Immunofluorescence staining analyses

Serial tissue sections were cut from the paraffin-embedded formalin-fixed tumor tissue and subjected to immunofluorescence and hematoxylin and eosin (HE) histological staining. Briefly, tissue sections were deparaffinized, hydrated, and stained using antibodies against Groa (1:400; bs-0863R), NOD1 (1:20000; orb-77656), NOD2 (1:50, sc-56168) and RIPK2 (1:100, bs-3546R) (Bioss Antibodies, USA), respectively, and an IgG isotype antibody (Santa Cruz, CA) served as negative control; then corresponding secondary antibodies with FITC. The section was also stained with Hoechst 33342 (Promega) to study the nuclear morphology. The specific protein expressions and cell nuclei were investigated under a fluorescence microscope (Nikon, TE2000-U, Japan).

### Cell culture

HNSCC SCC25 cells were obtained from the American Type Culture Collection (Rockville, MD). OECM-1 (SCC180) human oral cavity SCC cells were kindly provided by Prof. Hamm-Ming Sheu (National Cheng Kung University Medical College, Tainan, Taiwan). HNSCC cells were maintained in Dulbecco's modified Eagle medium (DMEM)/F12; OECM-1 cells
were cultured in DMEM medium (GIBCO, Grand Island, NY) and 10% fetal bovine serum (FBS) (Hazelton Product, Denver, PA, USA). All cells were incubated at 37°C in a humidified atmosphere of 5% CO₂ in air.

**RNA extraction, quantitative real-time polymerase chain reaction (qRT-PCR) and reverse transcription-PCR (RT-PCR) analyses**

NCMT and HNSCC tissues RNA were extracted using the Total RNA Miniprep Purification Kit (GeneMark). To extract RNA from cultured cells, SCC25 and OECC-1 cells (1 × 10⁵ cells/ml) were treated with Groα (0, 1 and 10 nM) for 72 h, and then the RNA was isolated using the Trizol kit (Invitrogen, Carlsbad, CA, USA) and reverse transcribed using the PrimeScript™ 1st strand cDNA Synthesis Kit (Takara, Japan). qRT-PCR and RT-PCR were performed according to previously described protocol [9]. The following primer sequences were used as follows: Groα, 5′-ACGTGAAATCCCCCGAC-3′ and 5′-GCC CATTCTRAGTGTGCTCTC-3′; NOD1, 5′-GAGACTTGG CTCTCTCTTCCTC-3′ and 5′-CTGCCAGGCTCTCTG TGCT-3′; NOD2, 5′-AGCACATTGTCAGGGAAGCTC-3′, and 5′-CGCTCTGCTCTCATCACAGC-3′; RIPK2, 5′- CCATTGAGATTCGCCATCCCT-3′ and 5′-ATGCCGCC ACTTTGATAAAAC-3′; TNF-α, 5′-TTCTTCTACCT ACACACATTACCC-3′ and 5′-TGCCCGATTACCAGC AACAGTCC-3′; COX2, 5′-TGAACATCTACTGCTGTTT GCTG-3′ and 5′-TGCTTGCTGAAACAACTGC-3′; JNK, 5′-CTGAGCAGAAAGCTCACCA-3′ and 5′-CACCCTAAAGGAGGCTCTG-3′; ERK1/2, 5′-GCT CACCCTTACCTGACA-3′ and 5′-GGACCAAG TCCAAAAGACATAA-3′; p38, 5′-ATGAGGCTCTC ACAAAGC-3′ and 5′-GACACTAAAAGGAGGGCTC TGA-3′; and β-actin, 5′-TCACCACACTGTCGCACTCA TCC-3′ and 5′-CAGCGGAACCGCTCATTGC ACT-3′. The amplified RT-PCR products were electrophoresed on a 2% agarose gel, visualized by ethidium bromide staining and photographed under ultraviolet light. The relative expressions were determined by densitometry using the Image J software program, and normalized relative to β-actin.

**Statistical analysis**

All numerical data were taken as mean ± standard deviation (SD). Student’s t-test and one-way ANOVA were used to analyze the assays. Differences were considered statistically significant at p ≤ 0.05. The data were analyzed and plotted using software (SigmaPlot Version 8.0 and SigmaStat Version 2.03, Chicago, IL).

**Results**

**GROα induces NOD-mediated signaling in HNSCC metastasis**

In order to understand the factors of the CXC family of the inflammatory pathway in HNSCC, we searched the expression profile of the CXC family by using the UALCAN database. The expression of Groα and CXCL14 had higher expression in the HNSCC tumor (Fig. 1a). However, previous studies suggested CXCL14 expression had a negative association with all proinflammatory cytokines [16].

Besides, Groα was significantly higher in the grade 4 HNSCC tumor sample compared with that in grade 1-3 and normal samples (Fig. 1b). The abnormal expression of Groα may be associated with HNSCC progression. The online GEPIA tool analysis TCGA database indicates that the expressions of Groα, NOD1, NOD2 and RIPK2 in the cancer sample (n = 519) are higher than those of in the normal tissue (n = 44) (Fig. 1c). High Groα, NOD1 and RIPK2 levels also correlate with survival rate with HNSCC patients, especially Groα and RIPK2 (Fig. 1d). The patients were divided into early-stage and late-stage by number of lymph node metastasis and then we used the UALCAN database to analyze the statistical comparison of the Groα expression levels between the early- and late-stage. Analysis of HNSCC in the UALCAN database, the Groα expression between N0 and N3 (p < 0.02), was statistically significant.
In addition, multiple-gene comparison analysis verified that the expression of these four genes in HNSCC samples was also higher than that in normal samples, indicating the potential of these genes in the diagnosis of HNSCC (Fig. 2a).

Groα expression in HNSCC was further analyzed. The mRNA expression levels of Groα in 62 human NCMT and HNSCC tissues were compared by qRT-PCR. Groα expression was significantly higher (18.2-fold) in HNSCC tissues than in NCMT ($p < 0.05$) (Fig. 2b). Microarray analysis was used to assess the mRNA expression of CXCL1 in NCMT and HNSCC tissues to verify the results of qRT-PCR analysis. As shown in Fig. 1b, the Groα level was higher (22.3-fold and 3.3-fold, respectively) in early-stage (cT2N0M0, patient no. 1) and late-stage (cT3N3bM0, patient no. 2).
HNSCC than in NCMT tissues. These results suggest that Groα exhibited a cancer-specific response in HNSCC. Heatmap analysis showed the change of chemokines difference in early or the late stage of HNSCC. Groα was the highest of the CXC chemokine family in late stage and it was also a significantly upregulated expression between early or the late stage (Fig. S1).

Figure 2. Groα and NOD-mediated signaling is strongly correlated with HNSCC progression. a Multiple-gene comparison was analyzed by using GEPIA, and the density of color represented the expression level of genes. b qRT-PCR was used to analyze Groα mRNA expression in 62 human HNSCC and NCMT tissues. Groα was more highly expressed
in HNSCC than in NCMT. c) Microarray analyses of the expression and fold-change thresholds of Groα, NOD1, NOD2 and RIPK2 in HNSCC and NCMT tissue (patients no. 1 and 2). NOD1 and RIPK2 expressions in advanced HNSCC were > 2 times higher than in NCMT, but NOD2 expression was only 1.4 times higher. d) Groα, NOD1, NOD2 and RIPK2 expressions were higher in late-stage HNSCC (patient no. 4) than in early-stage HNSCC (patient no. 3), as confirmed by HE staining and immunofluorescence staining under an inverted fluorescent microscope (200× magnification). Levels of Groα, NOD1, NOD2 and RIPK2 in early-stage (E) (patient no. 5) and late-stage (L) (patient no. 6) HNSCC tissues were obtained using e) RT-PCR and f) western blot analysis. The expressions of Groα, NOD1 and RIPK2 in advanced HNSCC were significantly higher than in early-stage HNSCC, while the difference in the expression of NOD2 was not significant. Quantitative data reveal the L-HNSCC mRNA and protein level fold changes relative to E-HNSCC, as determined by densitometry. β-actin was used as a loading control.

Previous reports have found that NODs are functionally expressed in oral SCC cells and can trigger innate immune responses [9]. The level of NOD1 in gastric tumor tissues is regulated above that in paired non-tumor samples [17]. Our previous study demonstrated that NOD1 and RIPK2 expressions were higher in HNSCC tissue than NCMT, whereas NOD2 was weakly expressed in HNSCC tissue [9]. In this investigation, an array analysis revealed that NOD1 and RIPK2 expressions in advanced HNSCC (cT3N3bM0, patient no. 2) were significantly up-regulated (> 2 times) above those in NCMT, being 5.4 and 2.1 times greater, respectively, but NOD2 was weakly expressed (1.4-fold) (Fig. 2c). Therefore, Groα, NOD1 and RIPK2 perform significantly better in early- or late-stage HNSCC than in NCMT.

The expression levels of Groα, NOD1, NOD2 and RIPK2 in early- and late-stage HNSCC tissues were evaluated using immunofluorescence staining analysis (Fig. 2d). The expression levels in late-stage HNSCC (patient no. 4) exceeded those in early-stage HNSCC (patient no. 3). The cytoplasm localization of Groα, NOD1, NOD2 and RIPK2 was associated with more consistent and stronger expression in advanced HNSCC than in early-stage HNSCC. RT-PCR and western blot analysis confirmed that the expressions of genes and proteins of Groα and the NOD1/2-mediated RIPK2 pathway were higher in late-stage (patient no. 6) than in early-stage (patient no. 5) HNSCC tissues (Figs. 2e and 2f). The expressions of Groα, NOD1 and RIPK2 in advanced HNSCC significantly exceeded those in early-stage HNSCC, while the difference in expressions of NOD2 was not as great significant. The experimental results confirmed that HNSCC was associated with consistent and strong Groα and NOD-mediated signaling expression.

To define the NOD-mediated signaling pathway that is associated with Groα treatment, the gene and protein expressions of NOD1, NOD2 and RIPK2 in two types of HNSCC cells that had been treated with Groα for 72 h were obtained by RT-PCR and western blot analysis. As indicated in Figs. 3a and 3b, the exposure of SCC25 and OECEM-1 cells to Groα (0, 1 and 10 nM) increased the expression of NOD1 and RIPK2 in a concentration-dependent manner.
However, the expression of NOD2 in both types of HNSCC cells was unaffected by Groα treatment or weak as a result thereof. This finding suggests that the induction of HNSCC cancer progression by Groα is partially caused by the activation of NOD1 signaling partner RIPK2.

**GROα upregulates expressions of inflammatory mediator’s TNF-α and COX-2 in HNSCC**

A recent study showed that the immediate response of NOD activation might be caused by the production of TNF-α through NF-kB, TLR, and/or NOD signaling [18]. In the present study, microarray technology demonstrated that the expressions of TNF and COX-2 genes in advanced HNSCC (patient no. 2) were significantly higher (3.6 and 5.4-fold) than in NCMT (Fig. 4a). RT-PCR and western blot analysis confirmed that the expressions of genes and proteins of TNF-α and COX-2 were higher in late-stage (patient no. 8) than in early-stage HNSCC tissues (patient no. 7) (Figs. 4b and 4c). TNF-α and COX-2 levels were higher (3.2 and 1.8-fold by RT-PCR, respectively; 3.8-, and 2.7-fold by western blot, respectively) in late-stage than in early-stage HNSCC tissues.

To identify the inflammatory mediator that is associated with Groα treatment in HNSCC, the expressions of TNF-α and COX-2 in SCC25 and OECM-1 cells that were treated with Groα (0, 1 and 10 nM) for 72 h were determined by RT-PCR and western blot analysis. Treatment with Groα (10 nM) increased the TNF-α and COX-2 levels 2.5-fold in SCC25 cells, and 3.7-fold and 2.0-fold respectively, in OECM-1, according to RT-PCR (Fig. 5a); and 3.5-fold and 4.2-fold respectively in SCC25 cells, and 3.0-fold and 3.2-fold respectively in OECM-1, according to western blotting (Fig. 5b). These results suggest that Groα regulates inflammatory response by modulating TNF-α and COX-2 expressions in HNSCC.

**GROα upregulates MAPK signaling pathway in HNSCC**

By analyzing the correlated genes in the HNSCC, the NOD1 and RIPK2 mRNA levels showed a positive correlation between ERK, JNK and p38 mRNA in the TCGA dataset (Fig. 6a). A previous report established that TNF-α induces Groα expression through the JNK, p38 MAPK and PI-3K/Akt signaling pathways in human pulmonary epithelial cells [15]. To elucidate the association between Groα and the MAPK-mediated signaling pathway in HNSCC progression, the levels of JNK, ERK and p38, which are regulated in response to Groα, were determined in HNSCC cells. Upon exposure of SCC25 and OECM-1 cells to Groα (0, 1 and 10 nM) for 72 h, the expressions of JNK, ERK and p38 were determined by western blot and RT-PCR. Treatment with Groα increased JNK, ERK and p38 expressions in SCC25 cells and OECM-1 cells in a dose-dependent manner (Figs. 6b and 6c). Treatment with Groα (10 nM) increased JNK, ERK1/2 and p38 mRNA levels 2.4-, 5.2- and 2.3-fold respectively in SCC25 cells, and 2.6-, 2.8- and 2.5-fold respectively in OECM-1 cells (Fig. 6b). Western blot analysis was carried out to determine the expression of proteins p-JNK, p-ERK and p-p38 in Groα-treated HNSCC cells to verify the results of RT-PCR. Treatment with Groα (10 nM) increased the p-JNK, p-ERK and p-p38 levels 3.5-, 5.2- and 3.6-fold respectively in SCC25 cells, and 3.1-, 3.1- and 5.5-fold respectively in OECM1, according to western blotting (Fig. 6c). These results indicate that Groα induces TNF-α and COX-2 expression through regulation involving JNK-, ERK- and p38 MAPK-dependent signaling pathways.

---

**Figure 4.** Expressions of inflammatory mediators TNF-α and COX-2 in advanced HNSCC. a. Microarray analysis tests were used to evaluate the expression and fold-change thresholds of TNF-α and COX-2 in HNSCC and NCMT tissue (patient no. 2). TNF-α and COX-2 expressions in advanced HNSCC were > 2 times higher than in NCMT. Levels of TNF-α and COX-2 in early-stage (E-) (patient no. 7) and late-stage (L-) (patient no. 8) HNSCC tissues were obtained using b RT-PCR and c western blot analysis. Expressions of TNF-α and COX-2 in advanced HNSCC were significantly higher than in early-stage HNSCC. Quantitative data display L-HNSCC mRNA and protein fold changes relative E-HNSCC, as determined by densitometry. β-actin was used as a loading control.
Figure 5. Groα stimulates expression of inflammatory mediators TNF-α and COX-2 in HNSCC. Upon exposure of SCC25 and OECM-1 cells to Groα (0, 1 and 10 nM) for 72 h, levels of TNF-α and COX-2 were obtained using a RT-PCR and b western blot analysis. Treatment with Groα significantly increased TNF-α and COX-2 expressions in SCC25 and OECM-1 cells. Data reveal mRNA and protein fold-changes relative to untreated controls. β-actin was used as a loading control.

Discussion

Our previous cytokine array analysis study demonstrated that the expressions of IL-1β, IL-6, IL-8 and TNF-α in HNSCC (stage II) were significantly up-regulated > 2 times those in NCMT, and the up-regulation of IL-8 was the most significant. The expression of IL-8 was increased by a factor of 9.9 [19]. The expressions of secreted proteins in early- and late-stage HNSCC were compared herein to those in NCMT tissues. The Groα levels in the early-stage and late-stage HNSCC were higher (22.3-fold and 3.3-fold) than that in NCMT tissues. Levels were significantly higher in patients with HNSCC than in healthy subjects, suggesting that Groα was the most significantly differentially expressed chemokine.

NOD1 has an important role not only in defending hosts against pathogens but also in maintaining tissue homeostasis by regulating cell apoptosis, and the inflammatory and tissue repair responses to injury. The dysregulation of NOD1 signaling can cause persistent infection and chronic inflammation due to insufficient pathogen clearance, while chronic inflammation can initiate and promote cancer development [20]. Disrupting the function of NOD1 makes MCF-7 breast cancer cells resistant to apoptotic cell death and promotes tumor growth in the body [21]. NOD1 is thought to recruit the downstream effector RIPK2, which is not only a crucial in NOD1 signaling but also an important regulator of cellular proliferation, apoptosis and differentiation. A recent study found an association between RIPK2 polymorphism and the risk of urothelial cancer [22]. Activation of the effector kinase RIPK2 induces the NF-kB and the MAPK pathways, activating inflammatory genes and producing antimicrobial polypeptides, such as hBD1, 2, and 3 [8]. Therefore, RIPK2 plays an important role in mediating inflammation and innate immunity.

Our earlier investigation identified higher NOD1 and RIPK2 expressions in HNSCC tissue than in NCMT, but only weak NOD2 expression [9]. Human pharyngeal SCC (Detroit-562 and FaDu cells) exhibited strong expressions of NOD1 and NAIP but weak expressions of NOD2 and NLRP1 [23, 24]. FaDu cells displayed a lower Nod2 level and a higher NAIP level than healthy cells. In this study, Groα, NOD1, NOD2, and RIPK2 were significantly more strongly expressed in advanced HNSCC than in NCMT. Besides, the expressions of Groα, NOD1 and RIPK2 in advanced HNSCC were significantly higher than in early-stage HNSCC, while the difference in the performance of NOD2 was not significant. Groα, NOD1 and RIPK2 can potentially be used novel biomarkers for HNSCC carcinogenesis.

A recent study has shown that canonical members of the inflammatory senescence-associated secretory phenotype (SASP), such as IL1A, IL8, and Groα, are COX2-dependent. COX-2 is induced by pro-inflammatory cytokines at the site of inflammation and it promotes the COX-2-induced synthesis of prostaglandins; it stimulates cancer cell proliferation, promotes angiogenesis, and increases metastatic potential [25, 26]. Additionally, the incubation of a primary culture of astrocytes with TNF-α markedly increased the levels of several
chemokines, including CCL2 and CXCL1 [27]. TNF-α induces Groα expression in human A549 cells through transcriptional and nontranscriptional regulation that involves JNK-, p38 MAPK- and PI-3K/Akt-dependent signaling pathways [28]. These results demonstrate that Groα induces TNF-α and COX-2 expression through regulation that involves MAPK-dependent signaling pathways.

Figure 6. Groα stimulates expression of inflammatory mediators and upregulates MAPK signaling pathway in HNSCC. a Correlation analysis between NOD pathway (NOD1 and RIPK2) and inflammatory mediators (ERK, JNK, p38) in HNSCC samples from the GEPIA tool. Upon exposure of SCC25 and OECM1 cells to Groα (0, 0.1, 1 and 10 nM) for 72 h, levels of JNK, ERK and p38 MAPK were obtained using b RT-PCR and c western blot analysis. Exposure of SCC25 and OECM1 cells to Groα increased the expressions of JNK, ERK and p38 MAPK in a concentration-dependent manner. Data reveal mRNA and protein fold-changes relative to untreated controls. β-actin was used as a loading control.
Conclusion

Our findings constitute the first evidence that Groα is the major stimulus of inflammatory mediation and promotes TNF-α and COX-2 expression by activating NOD1/RIPK2-mediated JNK, ERK and p38 MAPK pathways in HNSCC progression and metastasis (Fig. 7). Future studies of the effects of Groα and NOD1-mediated MAPK signaling pathways that are associated with inflammation will establish their effectiveness as HNSCC biomarkers.

Abbreviations

CARD4: caspase activation recruitment domain 4; COX-2: cyclooxygenase-2; CXCL1: C-X-C motif chemokine ligand 1; CXC2: CXC receptor 2; ERK: extracellular signal-regulated kinase; GEPIA: Gene Expression Profiling Interactive Analysis; Groα: growth-related oncogene alpha; hBD: human β Defensin; HE: hematoxylin and eosin; HNSCC: head and neck squamous cell carcinoma; IFN: interferon; IL: interleukin; JNK: C-Jun N-terminal kinase; MAPK: mitogen-activated protein kinase; NCMT: non-cancerous matched tissue; NF-κB: nuclear factor kappa B; NLRs: nod-like receptors; NOD1: nucleotide-binding oligomerization domain 1; RIPK2: receptor-interacting serine-threonine kinase 2; SAPK: stress-activated protein kinase; SASP: senescence-associated secretory phenotype; TCGA: The Cancer Genome Atlas; TLRs: Toll-like receptors; TNF-α: tumor necrosis factor-α.

Supplementary Material

Supplementary figure. https://www.jcancer.org/v14p0989s1.pdf

Acknowledgements

This study was supported by grants from Ministry of Science and Technology (MOST110-2628-B-041-001), Kaohsiung Municipal Ta-Tung Hospital (KMTTH110-004 and KMTTH-111-001), Kaohsiung Municipal Siaogang Hospital/Kaohsiung Medical University Research Center grants (KMHK-DK(C)110009), Taiwan, and Kaohsiung Medical University Hospital/Kaohsiung Medical University Research Center grants (KMUH-DK(C)111008), Taiwan.

Author contributions

Leong-Perng Chan designed, performed research, interpreted and analyzed data as well as wrote the manuscript. Ya-Ping Tseng, Hui-Ching Wang, Chen-Yu Chien, Che-Wei Wu and Ling-Feng Wang provided technical and material support. Chia-Hua Liang edited the manuscript and supervised study.
Availability of data and materials

All data generated during this study are included in this published article and supplementary information files. Further details are available from the corresponding author upon request.

Ethics approval and consent to participate

Informed consent was obtained from all patients. This study was approved by the Kaohsiung Medical University Hospital.

Competing Interests

The authors have declared that no competing interest exists.

References